This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Powerful perspectives
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Press release
iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289
Data & publication
Safety and clinical activity of IOA-244, a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a Phase I first in human (FIH) study (study part A)
Data & publication
IOA-244 is a non-ATP-competitive, highly-selective, tolerable phosphoinositide-3-linase delta inhibitor that directly targets solid tumors and breaks immune tolerance
Data & publication
Non-ATP competitive inhibition of PI3δ with IOA-244 shows anti-lymphoma activity
Press release
iOnctura expands Advisory Board
Data & publication
Safety, pharmacokinetic (PK), pharmacodynamic (PD) and activity of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with follicular lymphoma (FL)
Data & publication
First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer
Press release
iOnctura to present at ASCO IOA-244 showing highly promising impact on overall survival for patients with metastatic and refractory uveal melanoma
Press coverage
BioWorld — IOA-244 to revive PI3K delta inhibitors?
Press release
iOnctura to present at ASCO encouraging Phase Ib refractory uveal melanoma data for first semi-allosteric PI3Kδ inhibitor, IOA-244
Data & publication
The role of CAF in promoting cancer cell proliferation
Data & publication
iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289
Looking for media
resources?